Quick Answer
Q32 Bio Inc. reported Operating Income Loss of $16.90 million for the year ending 2025.
- Q32 Bio Inc. showed an increase of +125.6% in Operating Income Loss from 2024 to 2025.
- This data is from Q32 Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$4.69 million | Q2 2017: -$6.04 million | Q3 2017: -$6.66 million | Q1 2018: -$10.70 million | Q2 2018: -$13.42 million | Q3 2018: -$15.64 million | Q1 2019: -$25.12 million | Q2 2019: -$27.97 million | Q3 2019: -$31.29 million | Q1 2020: -$36.49 million | Q2 2020: -$35.70 million | Q3 2020: -$28.27 million | Q1 2021: -$1.11 million | Q2 2021: -$30.55 million | Q3 2021: -$30.66 million | Q1 2022: -$37.62 million | Q2 2022: -$28.31 million | Q3 2022: -$32.86 million | Q1 2023: -$7.37 million | Q2 2023: -$7.28 million | Q3 2023: -$7.80 million | Q1 2024: -$14.84 million | Q2 2024: -$17.92 million | Q3 2024: -$18.81 million | Q1 2025: -$12.23 million | Q2 2025: -$9.17 million | Q3 2025: -$7.58 million.
- Over the full 9 years of available data (2017 to 2025), Q32 Bio Inc.'s Operating Income Loss has grown by 157.0%.
- Historical annual values: Fiscal year 2025: $16.90 million | Fiscal year 2024: -$66.10 million | Fiscal year 2023: -$48.26 million | Fiscal year 2022: -$133.28 million | Fiscal year 2021: -$95.95 million | Fiscal year 2020: -$130.26 million | Fiscal year 2019: -$109.94 million | Fiscal year 2018: -$59.93 million | Fiscal year 2017: -$29.66 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: